Biología molecular en el diagnóstico y el pronóstico del cáncer de pulmón
small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2010; 5: 436-41. 7. Brambilla C, Laffaire J, Lantuejoul S, et al. Lung squamous cell carcinomas with basaloid histology represent a specific molecular entity. Clin Cancer Res Off J Am Assoc Cancer Res. 2014; 20: 5777-86. 8. Caplin ME, Baudin E, Ferolla P, et al. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2015; 26: 1604-20. 9. French CA. Demystified molecular pathology of NUT midline carcinomas. J Clin Pathol. 2010; 63: 492-6. 10. Jin Y, Wang J, Ye X, et al. Identification of GlcNAcylated alpha-1-antichymotrypsin as an early biomarker in human non-small-cell lung cancer by quantitative proteomic analysis with two lectins. Br J Cancer. 2016; 114: 532-44. 11. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008; 359: 1367-80. 12. Sheervalilou R, Ansarin K, Fekri Aval S, et al. An update on sputum MicroRNAs in lung cancer diagnosis. Diagn Cytopathol. 2016; 44: 442-9. 13. Taverna S, Giallombardo M, Gil-Bazo I, et al. Exosomes isolation and characterization in serum is feasible in non-small cell lung cancer patients: critical analysis of evidence and potential role in clinical practice. Oncotarget. 2016; 7: 28748-60. 14. National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lungcancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365: 395-409. 15. Callister MEJ, Baldwin DR, Akram AR, et al. British Thoracic Society guidelines for the investigation and management of pulmonary nodules. Thorax. 2015; 70(Suppl 2): ii1-54. 16. Shen J, Liu Z, Todd NW, et al. Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. BMC Cancer. 2011; 11: 374. 17. Wang C, Ding M, Xia M, et al. A Five-miRNA Panel Identified From a Multicentric Case-control Study Serves as a Novel Diagnostic Tool for
49
Ethnically Diverse Non-small-cell Lung Cancer Patients. EBioMedicine. 2015; 2: 1377-85. 18. Daly S, Rinewalt D, Fhied C, et al. Development and validation of a plasma biomarker panel for discerning clinical significance of indeterminate pulmonary nodules. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2013; 8: 31-6. 19. Higgins G, Roper KM, Watson IJ, et al. Variant Ciz1 is a circulating biomarker for early-stage lung cancer. Proc Natl Acad Sci U S A. 2012; 109: E3128-35. 20. Puchades-Carrasco L, Jantus-Lewintre E, PérezRambla C, et al. Serum metabolomic profiling facilitates the non-invasive identification of metabolic biomarkers associated with the onset and progression of non-small cell lung cancer. Oncotarget. 2016; 7: 12904-16. 21. Lam S, Boyle P, Healey GF, et al. EarlyCDTLung: an immunobiomarker test as an aid to early detection of lung cancer. Cancer Prev Res Phila Pa. 2011; 4: 1126-34. 22. Jett JR, Peek LJ, Fredericks L, Jewell W, Pingleton WW, Robertson JFR. Audit of the autoantibody test, EarlyCDT®-lung, in 1600 patients: an evaluation of its performance in routine clinical practice. Lung Cancer Amst Neth. 2014; 83: 51-5. 23. Molina R, Marrades RM, Augé JM, et al. Assessment of a Combined Panel of Six Serum Tumor Markers for Lung Cancer. Am J Respir Crit Care Med. 2016; 193: 427-37. 24. Silvestri GA, Vachani A, Whitney D, et al. A Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer. N Engl J Med. 2015; 373: 243-51. 25. Passiglia F, Bronte G, Castiglia M, et al. Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls? Expert Opin Biol Ther. 2015; 15: 1553-66. 26. Plönes T, Engel-Riedel W, Stoelben E, Limmroth C, Schildgen O, Schildgen V. Molecular pathology and personalized medicine: The dawn of a new era in companion diagnostics-practical considerations about companion diagnostics for non-small-cell-lung-cancer. J Pers Med. 2016; 6. 27. Arteaga CL. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol. 2002; 29: 3-9. 28. Hirsch FR, Varella-Garcia M, Cappuzzo F. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene. 2009; 28(Suppl 1): S32-7.